Skip to main content

Journey Medical Corp

DERM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001867066

No open-market purchases or sales by Journey Medical Corp insiders were filed in the last 90 days; 71 institutions reported holding it in 13F filings for Q2 2026, worth $75.2M in total; no superinvestor holds it.

Q3 2022 vs. Q2 2022

How the institutions holding Journey Medical Corp changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of DERM: Q2 2022 compared with Q3 2022
MeasureQ2 2022Of which not filed for Q3 2022Q3 2022Change
Holders13120+8
Shares1.76M15.0K1.88M+134.2K (+7.7%)
Value$6.52M$0$4.62M−$1.90M (−29.2%)

1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (8)

Institutions that held Journey Medical Corp at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to DERM in Q3 2022
InstitutionSharesValue% of portfolio
First Manhattan Co35,294$86.0K0.00%
Geode Capital Management, LLC27,555$67.0K0.00%
Cerity Partners LLC25,421$63.0K0.00%
Susquehanna International Group, LLP22,094$54.0K0.00%
Wealth Alliance Advisory Group, LLC21,500$53.0K0.02%
National Asset Management, Inc.17,250$43.0K0.00%
Buckingham Strategic Partners10,000$25.0K0.00%
Royal Bank of Canada47$00.00%

Sold out (0)

Institutions that held Journey Medical Corp at the end of Q2 2022 and filed for Q3 2022 without it.

None.

Not filed for Q3 2022 yet (1)

Institutions that held Journey Medical Corp at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding DERM in Q2 2022 that haven't filed for Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
B. Riley Wealth Management, Inc.15,000–